Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.74 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.65 |
| ▸ | GRK6 | P43250 | 2/20 | 0.58 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.55 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.49 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | VDR | P11473 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505403 | 0.90 | NR1H2 (0.59) | NR1H2NR1H3ADORA2AADORA1GRK6 | |
| SCHEMBL17279794 | 0.87 | NR1H2 (0.86) | NR1H2NR1H3ADORA2AADORA1GRK6 | |
| SCHEMBL12171904 | 0.86 | NR1H2 (0.54) | NR1H2NR1H3ADORA2AADORA1GRK6 | |
| SCHEMBL30149870 | 0.85 | NR1H2 (0.89) | NR1H2NR1H3ADORA2AADORA1GRK6 | |
| SCHEMBL29035880 | 0.85 | NR1H2 (0.89) | NR1H2NR1H3ADORA2AADORA1GRK6 | |
| SCHEMBL12171118 | 0.84 | NR1H2 (0.64) | NR1H2NR1H3ADORA2AGRK6MAPT | |
| SCHEMBL21834365 | 0.82 | GRK6 (0.62) | NR1H2NR1H3ADORA2AADORA1GRK6 | |
| SCHEMBL17348266 | 0.81 | NR1H2 (0.60) | NR1H2NR1H3ADORA2AADORA1MAPT | |
| SCHEMBL24242695 | 0.81 | NR1H2 (0.60) | NR1H2NR1H3ADORA2AMAPTSMN1; SMN2 | |
| SCHEMBL12798250 | 0.81 | NR1H2 (0.60) | NR1H2NR1H3ADORA2AGRK6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2939674-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-2311455-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301536-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301538-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | NR1H2 4481/4885NR1H3 4544/4885ADORA2A 4310/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | NR1H2 4389/4885NR1H3 4459/4885ADORA2A 4417/4885 |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | NR1H2 3235/4885NR1H3 3307/4885ADORA2A 1850/4885 |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | NSUN2, UPF1, NSUN3 | NR1H2 3235/4885NR1H3 3307/4885ADORA2A 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.